Cryoport has been selected by DiscGenics to provide logistics support to its multicenter, first-in-human study to evaluate the safety and preliminary efficacy of IDCT, its allogeneic injectable cell therapy, in patients with single level, symptomatic lumbar intervertebral disc degeneration. Cryoport’s temperature-controlled logistics support services will include outbound logistics for DiscGenics’ clinical phase 1/2 trial of IDCT to clinics in both the U.S., and eventually Japan. ...